152 related articles for article (PubMed ID: 7295882)
41. Determination of the two mononitrate metabolites of isosorbide dinitrate in human plasma and urine by gas chromatography with electron-capture detection.
Sioufi A; Pommier F
J Chromatogr; 1984 Jan; 305(1):95-103. PubMed ID: 6707157
[TBL] [Abstract][Full Text] [Related]
42. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
Thomson AH; Miller SH; Green ST; Whiting B
Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
[TBL] [Abstract][Full Text] [Related]
43. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R
Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia.
Hennig L; Andresen D; Hennig A; Levenson B; Brüggemann T; Schröder R
J Clin Pharmacol; 1991 Jul; 31(7):636-40. PubMed ID: 1894759
[TBL] [Abstract][Full Text] [Related]
45. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
[TBL] [Abstract][Full Text] [Related]
46. Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.
Rosseel MT; Bogaert MG
J Pharm Sci; 1979 May; 68(5):659-60. PubMed ID: 430513
[TBL] [Abstract][Full Text] [Related]
47. Determination of isosorbide dinitrate and its mononitrate metabolites in human plasma using Extrelut purification and capillary column gas-liquid chromatography.
Santoni Y; Rolland PH; Cano JP
J Chromatogr; 1984 Mar; 306():165-72. PubMed ID: 6715456
[TBL] [Abstract][Full Text] [Related]
48. [Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].
Frydman A; Levenson J; Simon A; Safar M; Bieder A; Bertharion J; Gaillot J
Nouv Presse Med; 1982 Jun; 11(27):2049-56. PubMed ID: 7110964
[TBL] [Abstract][Full Text] [Related]
49. Saliva concentrations of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate.
Taylor IW; Major RM; Chasseaud LF; Taylor T
Br J Clin Pharmacol; 1984 May; 17(5):585-7. PubMed ID: 6733004
[TBL] [Abstract][Full Text] [Related]
50. Long-acting isosorbide mononitrate.
Prakash A; Markham A
Drugs; 1999 Jan; 57(1):93-9; discussion 100. PubMed ID: 9951954
[TBL] [Abstract][Full Text] [Related]
51. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Storm G; Oosterhuis B; Bron J; Wittebrood AJ; De Jong AP; Jonkman JH
Biopharm Drug Dispos; 1991 Dec; 12(9):661-72. PubMed ID: 1790311
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel HC; Volkenandt M; Steudel AT
Z Kardiol; 1983; 72 Suppl 3():24-8. PubMed ID: 6666228
[TBL] [Abstract][Full Text] [Related]
53. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
Menke G; Schnellhammer R; Rietbrock N
Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
[TBL] [Abstract][Full Text] [Related]
54. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
[TBL] [Abstract][Full Text] [Related]
55. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.
Abshagen U; Spörl-Radun S
Eur J Clin Pharmacol; 1981; 19(6):423-9. PubMed ID: 7250175
[TBL] [Abstract][Full Text] [Related]
56. Effects and pharmacokinetics of isosorbide dinitrate in normal man.
Spörl-Radun S; Betzien G; Kaufmann B; Liede V; Abshagen U
Eur J Clin Pharmacol; 1980 Oct; 18(3):237-44. PubMed ID: 7439242
[TBL] [Abstract][Full Text] [Related]
57. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
Thadani U
Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
[TBL] [Abstract][Full Text] [Related]
58. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker JO
Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
[TBL] [Abstract][Full Text] [Related]
59. [Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate].
Martsevich SIu; Semenova IuE; Alimova EV; Dmitrieva nA; Kozyreva MP; Koniakhina IP; Lukina IuV; Egorov VA
Kardiologiia; 2005; 45(11):42-5. PubMed ID: 16353064
[TBL] [Abstract][Full Text] [Related]
60. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
